Video

Dr. Memarzadeh on p53 Reactivation in Ovarian Cancer

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

Sanaz Memarzadeh, MD, PhD, gynecologic oncologist, professor of obstetrics and gynecology, University of California, Los Angeles, discusses p53 reactivation in the treatment of patients with ovarian cancer.

There are 3 approaches that are being taken to restore p53 function. Many of these approaches are focused on restoring p53 folding, Memarzadeh says. It has to be a tetramer and properly folded, so that it can bind to DNA. APR-246 is 1 of the first drugs being tested. The drug was found in a drug screen specifically targeting cells that carry a type of p53 mutation. The compound, states Memarzadeh, has to be converted to methylene quinuclidinone. It then binds to cystines in either p53 or any molecule that carries a cystine. By doing so, it is thought to restore the folding and subsequent function of p53.

This is being tested in clinical trials in combination with other agents. The exact mechanism of action is unknown, states Memarzadeh, which underscores the need for biomarkers of response.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity